China’s NDRC Issues Anti-Monopoly Law's Priciest Fine Ever On Two Chinese Firms Manipulating Raw Ingredient Sales
This article was originally published in PharmAsia News
Executive Summary
Is NDRC sending a message that the pharma industry is too important to be left to industry regulation alone?